Zim Laboratories Files Q4 & FY26 Earnings Presentation
Zim Laboratories reported Q4 FY26 revenue of ₹1,053 million and FY26 revenue of ₹3,744 million. FY26 EBITDA was ₹414 million, with a margin of 11.1%. The company received approval for Dabigatran Etexilate in Italy in May 2026. An Advisory Board has been formed, and the company approved a preferential issue of shares aggregating ₹35 crore.
The announcement includes financial results with a year-on-year decline in key metrics, which is material for investors. The formation of an advisory board and a preferential share issuance also carry significant implications for the company's strategic direction and capital structure.
The company reported a decline in revenue and profitability for Q4 and FY26 compared to the previous year, primarily due to geopolitical issues and increased costs. While there were positive developments like regulatory approvals and strengthening of governance, the overall financial performance was impacted.
Zim Laboratories Limited has submitted its Q4 and FY26 Earnings Presentation to the stock exchanges. The presentation details the company's financial performance for the fourth quarter and the full fiscal year 2026.
For the full year FY26, Total Operating Income stood at ₹3,744 million, a decrease of 1.2% compared to FY25. EBITDA was ₹414 million, down 16.4% year-on-year, with the EBITDA margin at 11.1%, a decrease of 200 basis points from 13.1% in FY25. The company attributed increased costs to geopolitical issues, general inflation in raw materials, utilities, and employee costs, as well as the onboarding of experienced senior management talent. Profit After Tax (PAT) for FY26 was ₹58 million, a decline from ₹122 million in FY25, impacted by lower EBITDA, increased depreciation, and finance costs from capital expenditures.
In Q4 FY26, Total Operating Income was ₹1,053 million, a decrease of 3.2% compared to Q4 FY25. EBITDA for the quarter was ₹134 million, down 18.1% year-on-year, with the EBITDA margin at 12.7%, a decrease of 230 basis points from 15.0% in Q4 FY25. PAT for Q4 FY26 was ₹37 million.
The presentation also highlighted regulatory momentum, with 57 total filings and 34 Marketing Authorizations (MAs) received in FY26. The company received an MA for its NIP Dabigatran Etexilate capsules in Italy in May 2026. The company has strengthened its governance with the formation of an Advisory Board comprising three distinguished industry leaders and has also strengthened its senior management team with four key hires in International, Quality, HR, and Procurement over the last 12 months.
Regarding CAPA remediation, most of the plan has been completed and implemented, with Q4 FY26 showing progress in validation by consultants and initiatives for triggering audits from other regions. The company also announced the Board's approval for the issuance of 47,64,497 equity shares at ₹73.46 per share to Florintree Trinex LLP on a preferential basis, aggregating up to ₹35 crore.
What to do with a filing like this
Zim Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zim Laboratories Limited. Read the original for the full detail.